Coll, Rebecca C. http://orcid.org/0000-0002-7359-6023
Hill, James R. http://orcid.org/0000-0001-9592-2283
Day, Christopher J.
Zamoshnikova, Alina
Boucher, Dave
Massey, Nicholas L.
Chitty, Jessica L.
Fraser, James A.
Jennings, Michael P. http://orcid.org/0000-0002-1027-4684
Robertson, Avril A. B. http://orcid.org/0000-0002-9652-8357
Schroder, Kate http://orcid.org/0000-0001-9261-3805
Article History
Received: 8 July 2018
Accepted: 22 March 2019
First Online: 13 May 2019
Competing interests
: R.C.C., A.A.B.R. and K.S. are co-inventors on patent applications for NLRP3 inhibitors (WO2018215818, WO2017140778 and WO2016131098), which are licensed to Inflazome Ltd, a company headquartered in Dublin, Ireland. Inflazome is developing drugs that target the NLRP3 inflammasome to address unmet clinical needs in inflammatory disease.